SMO and non-small cell lung carcinoma: In NSCLC, blocking the Hh signaling pathway using the SMO antagonist (SANT-1) restores the expression of E-cadherin; meanwhile, it decreases the expression of Snail and ABCG2 in EGFR-TKIs resistant NSCLC cells.